A randomized, open-label multicentre phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine cyclophosphamide and rituximab versus fludarabine cyclophosphamide and rituximab versus fludarabine cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.

Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC

http://www.ncbi.nlm.nih.gov/pubmed/25130401